ClinicalTrials.gg
Not yet recruitingNCT07947888TPOG-GCT-AFPUpdated Nov 19, 2026

Alpha-Fetoprotein Decline Kinetics in Children With Extracranial Malignant Germ Cell Tumors

An observational study in Germ Cell Tumor, Yolk Sac Tumor and Embryonal Carcinoma, sponsored by Ankara City Hospital Bilkent. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Ankara City Hospital Bilkent · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
400
Ages
Up to 17 Years
Sex
All
01

Study summary

Extracranial malignant germ cell tumors (GCTs) account for about 3% of childhood cancers. The current international risk classification (Malignant Germ Cell International Consortium, MaGIC) is based on age, primary tumor site and stage, and does not include how tumor markers respond during treatment. Serum alpha-fetoprotein (AFP) is measured routinely in nearly all of these children.

This national, multicenter, retrospective cohort study will evaluate whether the rate of AFP decline during first-line treatment predicts event-free survival independently of MaGIC risk factors. The medical records of children younger than 18 years diagnosed with an extracranial malignant non-germinomatous GCT between January 2014 and December 2025 and treated at participating pediatric oncology centers in Turkey will be reviewed. No new tests, samples, visits or interventions are required.

Secondary aims are to evaluate the prognostic value of AFP at diagnosis and of beta-human chorionic gonadotropin (beta-hCG) decline kinetics, to describe postoperative AFP kinetics in patients managed with surgery alone, to describe how relapses are detected, to quantify long-term treatment-related toxicity according to treatment intensity, and to explore a subgroup of patients who might be candidates for treatment reduction in future prospective studies.

Read the detailed description

Design: National, multicenter, retrospective cohort study coordinated by the Pediatric Hematology and Oncology Clinic of Ankara Bilkent City Hospital, conducted with the Turkish Pediatric Oncology Group (TPOG). Consecutive eligible patients diagnosed on or after 01 January 2014 whose first-line treatment ended on or before 31 December 2025 will be included, giving every patient at least 12 months of potential follow-up after the end of first-line treatment. The data lock date for follow-up is 31 December 2026. The study will be reported according to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) and REMARK (Reporting Recommendations for Tumor Marker Prognostic Studies) guidelines. The protocol, including pre-specified primary and secondary analyses, is registered before data collection begins.

Data collection: Local investigators at each participating center will abstract data from medical records and hospital information systems into a standardized, pseudonymized electronic case report form hosted on the coordinating center's institutional server in Turkey. No direct identifiers will be transferred to the coordinating center. Centers will enter only raw tumor marker values and dates; all derived variables (marker kinetics, age-adjusted AFP, MaGIC risk group, estimated glomerular filtration rate [eGFR]) will be calculated centrally with a single pre-specified analysis code. Data collected include demographics and predisposing conditions, tumor characteristics (site, World Health Organization [WHO] histology, stage by Children's Oncology Group [COG] or International Federation of Gynecology and Obstetrics [FIGO] criteria, International Germ Cell Cancer Collaborative Group [IGCCCG] risk group where applicable), surgery, chemotherapy and radiotherapy details including cumulative drug doses, all serial AFP, beta-human chorionic gonadotropin (beta-hCG) and lactate dehydrogenase (LDH) values with dates, liver function tests around AFP measurements, outcomes, and long-term toxicity.

AFP definitions: AFP values measured before 12 months of age will be interpreted using age-specific reference ranges for term and preterm infants, with continuous reference intervals derived from generalized additive models for location, scale and shape (GAMLSS) in sensitivity analysis. AFP at diagnosis will be expressed as log10 AFP and as multiples of the age-specific median (MoM).

Tumor marker kinetics: Serum AFP is measured on day 1 of each chemotherapy cycle before drug administration (each cycle is 21 days; generally 4 cycles, up to 6 cycles in some patients), at the end of first-line treatment and during follow-up, so that the AFP response is assessed after every cycle. (1) AFP half-life (primary kinetic exposure), calculated from the cycle 1 day 1 value with values in the first 7 days after chemotherapy start excluded to avoid surge; satisfactory decline is defined, consistent with the MaGIC definition, as normalization within the first two post-baseline measurements or a half-life of 7 days or less; (2) early decline ratio (cycle 2 day 1 / baseline); (3) observed-versus-expected decline area; (4) time to normalization; (5) patient-specific log-AFP slope from a linear mixed-effects model; (6) beta-hCG half-life (satisfactory if 3 days or less). Postoperative AFP kinetics will be calculated separately for patients managed with surgery alone.

Statistical analysis: Survival will be estimated by Kaplan-Meier and compared by log-rank test; cumulative incidence of relapse will be estimated with the Aalen-Johansen estimator (Gray test, Fine-Gray models in sensitivity analysis). To avoid immortal time bias, AFP kinetic analyses will use a landmark at the start of chemotherapy cycle 3 (each cycle is 21 days; approximately day 43 after the start of chemotherapy). Multivariable Cox models will be adjusted for MaGIC risk group, with a shared frailty term for center. Pre-specified interactions of AFP kinetics with age (\<11 vs >=11 years) and MaGIC risk group will be tested. A joint model of longitudinal log-AFP and time to event will be fitted as a complementary analysis. Incremental prognostic value will be assessed by Harrell's concordance index (C-index), time-dependent area under the receiver operating characteristic curve (AUC) at 3 years, calibration with bootstrap optimism correction, internal-external cross-validation by center when feasible, and decision curve analysis. Missing covariates will be handled by multiple imputation by chained equations (MICE); kinetic parameters will not be imputed.

Sample size: Assuming unsatisfactory AFP decline in about 12% of patients and a hazard ratio of 3.0 for event-free survival, 62 events are required for 80% power at two-sided alpha 0.05 (Schoenfeld method). With an event rate of about 15%, the target AFP kinetic cohort is approximately 320-420 patients. If fewer events occur, Firth's penalized likelihood will be used and results will be presented as exploratory.

Exploratory treatment-reduction analysis: Before any outcome data are analyzed, patients with MaGIC low- or standard-risk disease, satisfactory AFP decline and cisplatin-based chemotherapy will be defined as a candidate treatment-reduction subgroup. Relapse rates and long-term toxicity as a function of number of cycles and cumulative platinum dose will be described. This analysis is hypothesis-generating only.

02

Conditions studied

  • Germ Cell Tumor
  • Yolk Sac Tumor
  • Embryonal Carcinoma
  • Choriocarcinoma
  • Mixed Germ Cell Tumor
  • Childhood Cancer

Keywords

  • alpha-fetoprotein
  • tumor marker kinetics
  • AFP half-life
  • beta-hCG
  • MaGIC risk classification
  • event-free survival
  • late effects
  • treatment reduction
03

In context

Neoplasms, Germ Cell and Embryonal

166 studies on the registry are indexed under Neoplasms, Germ Cell and Embryonal; 48 are open to participants now.

This study's planned enrollment of 400 is above the median of 279 across 33 observational studies indexed under Neoplasms, Germ Cell and Embryonal.

Browse Neoplasms, Germ Cell and Embryonal studies →

Lead sponsor

Ankara City Hospital Bilkent is the lead sponsor of 450 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children and adolescents younger than 18 years diagnosed with an extracranial malignant non-germinomatous germ cell tumor between January 2014 and December 2025 and treated at participating pediatric hematology-oncology centers in Turkey (coordinating center: Ankara Bilkent City Hospital, including records of the former Ankara Children's Health and Diseases Hematology Oncology Training and Research Hospital). All consecutive eligible patients at each center will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age younger than 18 years at diagnosis.
  • Histopathologically confirmed extracranial malignant non-germinomatous germ cell tumor: yolk sac (endodermal sinus) tumor, embryonal carcinoma, choriocarcinoma, polyembryoma, mixed malignant germ cell tumor, or immature teratoma with a confirmed malignant component. Gonadal (ovary, testis) and extragonadal (sacrococcygeal, mediastinal, retroperitoneal, vaginal/uterine and other) primary sites are eligible.
  • Diagnosis on or after 01 January 2014 and completion of treatment on or before 31 December 2025. End of first-line treatment is the date of the last chemotherapy administration, or the date of definitive surgery for patients managed with surgery alone. Patients whose first-line treatment was stopped early because of progression, toxicity or death are also included, using the date of discontinuation.
  • First-line treatment (surgery alone or surgery plus chemotherapy) given at a participating center, with accessible treatment and follow-up records.

Exclusion criteria

Exclusion Criteria:

  • Primary central nervous system germ cell tumor.
  • Pure dysgerminoma (ovary) or pure seminoma (testis). Tumors reported as pure dysgerminoma/seminoma but with AFP above the age-specific upper limit at diagnosis are classified as mixed malignant germ cell tumors, included, and flagged for sensitivity analysis.
  • Pure mature or immature teratoma without a confirmed malignant component (pure immature teratomas with elevated AFP and no malignant focus are recorded in a separate exploratory module and excluded from the primary analyses).
  • Patients who completed treatment at a non-participating center and presented at relapse without accessible diagnostic/first-line treatment data.
  • Absence of histopathological confirmation.
  • Conditions that can independently raise serum AFP (hereditary tyrosinemia, ataxia-telangiectasia, active viral hepatitis, concurrent primary liver ).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children with extracranial malignant non-germinomatous germ cell tumors

    Patients younger than 18 years at diagnosis with a histologically confirmed extracranial malignant non-germinomatous germ cell tumor (yolk sac tumor, embryonal carcinoma, choriocarcinoma, polyembryoma, mixed malignant germ cell tumor, or immature teratoma with a malignant component), diagnosed on or after 01 January 2014 and completing first-line treatment (surgery alone or surgery plus chemotherapy) on or before 31 December 2025 at a participating center. Exposure of interest: serum AFP decline kinetics during first-line treatment (satisfactory vs unsatisfactory decline), as recorded during routine care. No study intervention is given.

06

What researchers measure

Primary outcomes

  1. Event-free survival according to alpha-fetoprotein (AFP) decline kinetics

    Association between unsatisfactory AFP decline during first-line treatment (AFP half-life \>7 days, or no normalization within the first two post-baseline measurements, consistent with the Malignant Germ Cell International Consortium \[MaGIC\] definition) and event-free survival, adjusted for MaGIC risk group (age, primary site, stage), estimated by hazard ratio from a multivariable Cox model with a landmark at the start of chemotherapy cycle 3 (each cycle is 21 days). AFP is measured on day 1 of each chemotherapy cycle before drug administration (generally 4 cycles, up to 6 cycles in some patients). Events: relapse, progression, second malignant neoplasm or death from any cause, whichever occurs first.

    Time frame: From the start of chemotherapy cycle 3 (each cycle is 21 days; approximately day 43 after the start of chemotherapy) to first event or last follow-up, assessed up to approximately 13 years (follow-up through 31 December 2026)

Secondary outcomes

  1. Overall survival

    Time from diagnosis to death from any cause, overall and according to AFP decline kinetics, adjusted for MaGIC risk group.

    Time frame: Follow-up up to 31 December 2026 (up to approximately 13 years from diagnosis)

  2. Cumulative incidence of relapse or progression

    Cumulative incidence of relapse or progression according to AFP decline kinetics, with death without relapse treated as a competing event (Aalen-Johansen estimator; Fine-Gray models in sensitivity analysis).

    Time frame: Follow-up up to 31 December 2026 (up to approximately 13 years from diagnosis)

  3. Prognostic value of AFP level at diagnosis

    Association of AFP at diagnosis (log10 AFP and multiples of the age-specific median) with event-free survival, beyond MaGIC risk group.

    Time frame: At diagnosis (exposure); outcome assessed through end of follow-up, up to 31 December 2026

  4. Incremental discrimination of AFP kinetics over the MaGIC model

    Change in Harrell concordance index (C-index) and time-dependent area under the receiver operating characteristic (ROC) curve at 3 years when AFP kinetic parameters are added to a MaGIC-only model, with bootstrap optimism correction and calibration assessment.

    Time frame: 3 years after the start of chemotherapy cycle 3 (each cycle is 21 days)

  5. Prognostic value of beta-human chorionic gonadotropin (beta-hCG) decline kinetics

    In patients with elevated beta-hCG at diagnosis, association of beta-hCG half-life (satisfactory if 3 days or less) with event-free survival.

    Time frame: Follow-up up to 31 December 2026 (up to approximately 13 years from diagnosis)

  6. Postoperative AFP kinetics in patients managed with surgery alone

    AFP half-life and time to AFP normalization after definitive surgery in patients managed with surgery alone and active surveillance, and their association with relapse.

    Time frame: From definitive surgery to AFP normalization or relapse; follow-up up to 31 December 2026

  7. Mode of relapse detection and AFP at relapse

    Proportion of relapses detected by tumor marker rise, imaging or clinical findings, and serum AFP level at relapse.

    Time frame: At relapse, through end of follow-up (31 December 2026)

  8. Long-term ototoxicity

    Proportion of patients with hearing loss by International Society of Paediatric Oncology (SIOP) Boston ototoxicity grade on the latest pure-tone audiometry, and hearing aid use, by regimen, number of cycles and cumulative platinum dose.

    Time frame: 12 months or more after the end of first-line treatment

  9. Long-term nephrotoxicity

    Proportion of patients with estimated glomerular filtration rate (eGFR) below 90 mL/min/1.73 m2 (bedside Schwartz equation) and persistent hypomagnesemia requiring supplementation, by treatment intensity.

    Time frame: 12 months or more after the end of first-line treatment

  10. Other long-term toxicities and surgical sequelae

    Peripheral neuropathy and bleomycin-related pulmonary toxicity graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; neurogenic bladder, bowel dysfunction and lower-extremity motor deficit.

    Time frame: 12 months or more after the end of first-line treatment

Other outcomes

  1. Relapse rate and toxicity in a candidate treatment-reduction subgroup (exploratory)

    Pre-specified before outcome analysis: patients with MaGIC low- or standard-risk disease, satisfactory AFP decline and cisplatin-based chemotherapy. Relapse rate will be estimated and long-term toxicity modeled as a function of number of cycles and cumulative platinum dose. Descriptive and hypothesis-generating only.

    Time frame: Follow-up up to 31 December 2026 (up to approximately 13 years from diagnosis)

07

Study locations

1 site
08

References and documents

Publications

  • Tran DM, Phan PH, Cao TV, Ngoc TT, Trinh DTP, Greaves RF, Loh TP, Tran MTC. Improving clinical interpretation of serum alpha-fetoprotein in children: using continuous and discrete reference intervals. Clin Chem Lab Med. 2026 Apr 15;64(8):1838-1848. doi: 10.1515/cclm-2026-0262. Print 2026 Jul 24. PubMed 41996693 ↗
  • O'Neill AF, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez-Galindo C, Frazier AL. alpha-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer. 2019 Oct 15;125(20):3649-3656. doi: 10.1002/cncr.32363. Epub 2019 Jul 29. PubMed 31355926 ↗
  • Blohm ME, Vesterling-Horner D, Calaminus G, Gobel U. Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age. Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):135-42. doi: 10.3109/08880019809167228. PubMed 9592840 ↗

Individual participant data

Plan to share: No — Under the approved ethics protocol and the Turkish Personal Data Protection Law (KVKK, Law No. 6698), pseudonymized data will be used only for this study, stored on the coordinating center's institutional server in Turkey, and will not be shared outside the study team. Data will be deleted or irreversibly anonymized after study completion.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947888
Collaborators
Turkish Pediatric Oncology Group
Responsible party
Emre Sefa Gültekin (Specialist in Pediatric Hematology and Oncology, Ankara City Hospital Bilkent) — Principal investigator
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Emre Sefa Gültekin, MD
Contact
esgpho@gmail.com
+90 312 552 6000
Derya Özyörük, MD, Prof.
principal investigator · Ankara City Hospital Bilkent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion